Clik here to view.
Beacon raises $170M to take on J&J in ocular gene therapy
Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson. J&J is ahead of...
View ArticleClik here to view.
Flagship appears to boost target of eighth fund by up to $500M
Flagship Pioneering, the sprawling life sciences investor and startup incubator, appears to be seeking more capital than originally planned for its eighth fund. The Boston-area firm is raising up to...
View ArticleSanofi and Regeneron’s Dupixent wins EU nod in COPD ahead of September PDUFA
Sanofi and Regeneron’s Dupixent has notched another indication in the EU, this time for a common lung disease, marking the first-ever targeted therapy for the condition in the region. The French...
View ArticleClik here to view.
Pfizer adds ex-State Street CEO to the board; Two Merus execs head for the exit
A few comings and goings before the Independence Day holiday in the US: Cyrus Taraporevala → Pfizer has welcomed former State Street Global Advisors president and CEO Cyrus Taraporevala to the board of...
View ArticleApollomics plans to lay off staff, narrow focus for lung cancer trial
Apollomics is making major cost cuts and leadership changes to stay afloat. The oncology biotech announced Wednesday morning that co-founder and president Sanjeev Redkar and chief medical officer Peony...
View ArticleClik here to view.
In biotech's uneven recovery, 50 startups raised megarounds in first half of...
The list of nine-figure financings for private biotechs is starting to look like the scrolling receipts from CVS or Walgreens. If that pace continues, it could top the heydays of 2020 and 2021. In the...
View ArticleMississippi judge rejects efforts by Novartis, PhRMA to block 340B state law
A Mississippi federal judge has denied efforts by Novartis and industry trade group PhRMA to thwart a state law that would keep drugmakers from imposing some restrictions around the federal drug...
View ArticleExperts want to make it easier to get RSV vaccines. Did they make it harder...
Last week, experts on the CDC’s panel that sets vaccine recommendations created new guidance for who should get RSV shots heading into the second-ever season of vaccination for the respiratory disease....
View ArticleFederal judge rules against Boehringer Ingelheim in IRA lawsuit
A Connecticut federal judge threw out Boehringer Ingelheim’s case against the Inflation Reduction Act on Wednesday, marking another win for the federal government as the first Medicare negotiations...
View ArticleRoche’s TIGIT drug tiragolumab fails Phase 3 lung cancer trial
Roche will halt a late-stage study of tiragolumab after it failed to help certain lung cancer patients, adding to a string of registrational disappointments for the drug in recent years. The anti-TIGIT...
View ArticleAvid Bio’s 2024 revenue drops; Lotte Bio breaks ground on new $3.3B site
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Avid Bioservices’ revenue for fiscal year 2024 dropped by 6% to $140...
View ArticleUK’s PMCPA criticizes Novo, Novartis, Pfizer and Otsuka for code breaches
A British watchdog has criticized four drugmakers, including Novo Nordisk, for violating the Association of the British Pharmaceutical Industry’s code of practice, marking the third time the Danish...
View ArticleInnovent reworks deal with IASO; Granza raises $7M
Plus, news about Kvantify: China’s Innovent takes a stake in CAR-T partner: After bringing the BCMA CAR-T therapy Fucaso to market in China, Innovent and IASO Biotechnology are reworking their deal....
View ArticleCircle Pharma raises $54M as part of Series D while macrocycles heat up
Circle Pharma, a startup working on macrocycles for the “undruggable,” is seeking about $117 million for a Series D. The company recently closed the first part of the round, reeling in about $54...
View ArticleEli Lilly’s Alzheimer’s OK; GSK picks its mRNA bets; Megaround tally;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly's support
On the verge of raising its Series A in late 2021, Myricx Bio faced a tough choice. The toxicity profile for its IV and oral small molecules looked “like a key risk,” according to Myricx CEO Robin...
View ArticleVC firm emerges to boost Austrian biotech scene that’s ‘ready to break out’
When Christopher Trummer tried raising money for his molecular glue degrader startup, he struggled to find VC support in his native Austria. The company, Celeris Therapeutics, had to leap to the US to...
View ArticleInventiva ramps up search for funding as cash runway erodes
As Inventiva continues to enroll patients into its Phase 3 liver disease program, it is seeking new funding to replenish its dwindling cash runway. The biotech had just €9.6 million ($10.4 million) in...
View ArticleClik here to view.
Lilly discloses its first biotech acquisition of the year, buying Morphic for...
Eli Lilly said Monday it plans to pay $3.2 billion in cash for Morphic Therapeutic, a biotech working on oral integrin drugs for chronic diseases, as the autoimmune space continues to drum up pharma...
View ArticleIdeaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397
Fresh Phase 2 data are adding weight to Ideaya Biosciences’ case for a targeted therapy it believes could be a first-in-class treatment option for certain types of urothelial cancer and lung cancer. In...
View Article